Get the latest news on Tasman Resources stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on TASEF performance

Latest Tasman Resources Stock News | OTC:TASEF | Benzinga

Tasman Resources Ltd is an Australian exploration company. The company is focusing on exploration projects with the potential to deposit a wide range of precious and base metals including gold, silver, copper, zinc, nickel, and uranium. Its projects are Lake Torrens Project, Pernatty Project and Vulcan prospect. The company's segments include Tasman Resources Ltd and Eden Innovations. It generates maximum revenue from the Eden Innovations segment.

TASMAN RESOURCES NL ORD by Tasman Resources NL

Tasman Resources Ltd

Tasman Resources

Transaction Represents Kamada&#39;s Entry into U.S. Plasma Collection Market and Advances the Company&#39;s Strategic Objective to Evolve into a&nbsp;Fully Integrated Specialty Plasma Company 
&nbsp;

Blood and Plasma Research, Inc.&nbsp;Primarily Focuses on Collecting Hyper-Immune Plasma, and Kamada Plans to Significantly Expand its Collection Capacity

REHOVOT, Israel, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:<a class="ticker" href="/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA))))), a plasma-derived biopharmaceutical company, today announced that it has entered into an agreement for the acquisition of the plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&amp;PR) of Beaumont, TX, USA. B&amp;PR&#39;s collection facility primarily specializes in the collection of hyper-immune plasma used for the Anti-D immunoglobulin, which is manufactured by Kamada and distributed in international markets. B&amp;PR&#39;s plasma collection center is one of the few FDA-licensed centers in the U.S. providing the raw materials required for this product.

&quot;The acquisition of this center represents our entry into the U.S. plasma collection market and furthers our strategic goal of becoming a fully integrated specialty plasma company,&quot; said Amir London, CEO of Kamada. &quot;We plan to significantly expand our hyperimmune plasma collection capacity by investing in B&amp;PR&#39;s center at Beaumont, TX, and leveraging its FDA license to open additional centers in the U.S. As demonstrated through the growth of our Anti-Rabies Immunoglobulin (IgG) product in the U.S. and other markets, our increased focus on anti-D sales internationally, and the rapid development and supply of our investigational COVID-19 IgG product, we are committed to growing our hyperimmune IgG portfolio. We believe this acquisition is a significant strategic step in that direction, and it is expected to improve our competitiveness in the different markets. We look forward to successfully growing this emerging business.&quot;

The acquisition for a total consideration of approximately&nbsp;$1.63 million, is expected to be consummated during this quarter, subject to closing conditions as set forth in the acquisition agreement, through Kamada Plasma LLC, a newly formed wholly owned subsidiary of Kamada, which will operate the plasma collection activity in the U.S.

Comments

Tasman Resources Stock News

News

Latest Tasman Resources Stock News | OTC:TASEF | Benzinga

Monday, February 01, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga